Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NTRK2 A203T |
Therapy | Larotrectinib |
Indication/Tumor Type | hematologic cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NTRK2 A203T | hematologic cancer | sensitive | Larotrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vitrakvi (larotrectinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |
PubMed Id | Reference Title | Details |
---|---|---|
(32315394) | Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. | Full reference... |